Tuesday , June 22 2021

▷ The Californian research team publishes promising results for a …



Santa Clara, California (PRNewswire / -) – A team of researchers from Dr. Ing. The Rath Research Institute of California has developed a cancer vaccine that reduces the growth of the tumor. This peptide-based vaccine points to specific enzymes called metalloproteinases (MMP), which are responsible for the growth of tumors, the formation of metastases and blood vessels in tumors (angiogenesis). Dr. The Rath research team demonstrated that the tested mice vaccinated with peptides containing specific sequences of MMP-2 and MMP-9 and subsequently infected with melanoma cancer cells had an average reduction of the tumor of about 76% compared to non- vaccinated Animals from the control group. Remarkably, some vaccinated animals did not develop any type of cancer.

The study was published in October 2018 in the online journal of Cellular Medicine and Natural Health.

Cancer is still the second world epidemic. The disease causes more than 7 million deaths every year. This new vision of therapy has the potential to drastically change these statistics. Compared with monoclonal antibodies (Mabs) or newly developed biosimilar molecules as anti-cancer agents, the anti-MMP vaccine approach promises to be much more effective and accessible in the global fight against disease. While mabs / biosimilares point to a specific type of cancer, the anti-MMP vaccine can fight all types of cancer. Another advantage is that, in contrast to Mabs / Biosimilars, where you usually have to make an injection once or twice a month, the MMP vaccine should be injected only once and a vaccination after several years would be necessary.

The anti-MMP vaccine, if successfully completed, could be offered to patients at national or international health centers at a reasonable cost.

In order for this valuable technology to be accessible to most patients and nations around the world, the Dr. Rath has applied for patent protection in many countries. The institute seeks public and government research institutions and other non-profit institutions to develop this promising technology with them, in order to successfully address, tackle preventively and eventually eliminate cancer.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

United States Patents 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Press contact:

Dr. Alexandra Niedzwiecki
CEO
Dr. Rath Research Institute
Email: [email protected]

Original content by: Dr. med. Rath Research Institute, transmitted by aktuell news


Source link